甲状腺癌

Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.全文  摘要

Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.全文  摘要

Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.全文  摘要

Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019 Mar 15;104(9):4087-100.全文  摘要

1. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016 Sep 15;375(11):1054-67.全文  摘要

2. Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.全文  摘要

3. Kure S, Ohashi R. Thyroid Hürthle cell carcinoma: clinical, pathological, and molecular features. Cancers (Basel). 2020 Dec 23;13(1):26.全文  摘要

4. Jannin A, Escande A, Al Ghuzlan A, et al. Anaplastic thyroid carcinoma: an update. Cancers (Basel). 2022 Feb 19;14(4):1061.全文  摘要

5. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.全文  摘要

6. Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013 Aug;98(8):3131-8.全文  摘要

7. Walsh S, Lowery AJ, Evoy D, et al. Thyroid lymphoma: recent advances in diagnosis and optimal management strategies. Oncologist. 2013;18(9):994-1003.全文  摘要

8. Tumours of the thyroid gland. In: Lloyd RV, Osamura RY, Klöppel G, et al, eds. WHO classification of tumours of endocrine organs. 4th ed, vol. 10. IARC; Lyon, France: 2017.

9. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017 Nov;27(11):1341-6.全文  摘要

10. Amin MB, Edge S, Green F, et al, eds. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

11. Brierley JD, Gospodarowicz MK, Wittekind C, eds; Union for International Cancer Control. TNM classification of malignant tumors. 8th ed. Chichester, UK: Wiley-Blackwell; 2017.

12. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018 Jan;68(1):55-63.全文  摘要

13. Bertagna F, Treglia G, Piccardo A, et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012 Nov;97(11):3866-75.全文  摘要

14. Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021 Mar;31(3):337-86.全文  摘要

15. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016 Dec 3;388(10061):2783-95. 摘要

16. Phillips JS, Pledger DR, Hilger AW. Rapid thyrotoxicosis in anaplastic thyroid carcinoma. J Laryngol Otol. 2007 Jul;121(7):695-7. 摘要

17. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-72. 摘要

18. James BC, Mitchell JM, Jeon HD, et al. An update in international trends in incidence rates of thyroid cancer, 1973-2007. Cancer Causes Control. 2018 May;29(4-5):465-73. 摘要

19. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: thyroid cancer. 2022 [internet publication].全文

20. Panato C, Vaccarella S, Dal Maso L, et al. Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. J Clin Endocrinol Metab. 2020 Aug 1;105(8):2507-14.全文  摘要

21. Wu J, Zhao X, Sun J, et al. The epidemic of thyroid cancer in China: current trends and future prediction. Front Oncol. 2022 Sep 2;12:932729.全文  摘要

22. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-34. 摘要

23. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-6.全文  摘要

24. Genere N, El Kawkgi OM, Giblon RE, et al. Incidence of clinically relevant thyroid cancers remains stable for almost a century: a population-based study. Mayo Clin Proc. 2021 Nov;96(11):2823-30.全文  摘要

25. Menicali E, Guzzetti M, Morelli S, et al. Immune landscape of thyroid cancers: new insights. Front Endocrinol (Lausanne). 2021 Apr 27;11:637826.全文  摘要

26. Prete A, Borges de Souza P, Censi S, et al. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne). 2020 Mar 13;11:102.全文  摘要

27. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.全文  摘要

28. Singh Ospina N, Iñiguez-Ariza NM, Castro MR. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ. 2020 Jan 7;368:l6670. 摘要

29. Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 2018 Jun;6(6):500-14. 摘要

30. Williams D. Thyroid growth and cancer. Eur Thyroid J. 2015 Sep;4(3):164-73.全文  摘要

31. Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019 Oct;8(5):227-45.全文  摘要

32. Liu J, Liu Y, Lin Y, et al. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab (Seoul). 2019 Sep;34(3):215-25.全文  摘要

33. Laha D, Nilubol N, Boufraqech M. New therapies for advanced thyroid cancer. Front Endocrinol (Lausanne). 2020 May 22;11:82.全文  摘要

34. Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019 Oct 25;20:324-36.全文  摘要

35. Drozd V, Saenko V, Branovan DI, et al. A search for causes of rising incidence of differentiated thyroid cancer in children and adolescents after Chernobyl and Fukushima: comparison of the clinical features and their relevance for treatment and prognosis. Int J Environ Res Public Health. 2021 Mar 26;18(7):3444.全文  摘要

36. Suteau V, Munier M, Briet C, et al. Sex bias in differentiated thyroid cancer. Int J Mol Sci. 2021 Nov 30;22(23):12992.全文  摘要

37. Schubart JR, Eliassen AH, Schilling A, et al. Reproductive factors and risk of thyroid cancer in women: an analysis in the Nurses' Health Study II. Womens Health Issues. 2021 Sep-Oct;31(5):494-502. 摘要

38. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009 Oct;89(5):1193-204.全文  摘要

39. Calcaterra V, Mameli C, Rossi V, et al. The iodine rush: over- or under-iodination risk in the prophylactic use of iodine for thyroid blocking in the event of a nuclear disaster. Front Endocrinol (Lausanne). 2022 May 26;13:901620.全文  摘要

40. National Institute for Health and Care Excellence. Thyroid cancer: assessment and management. Dec 2022 [internet publication].全文

41. American College of Radiology. ACR-AIUM-SPR-SRU practice parameter for the performance and interpretation of diagnostic ultrasound of the extracranial head and neck. 2022 [internet publication].全文

42. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. Eur J Radiol. 2019 Mar;112:14-21. 摘要

43. Hoang JK, Middleton WD, Tessler FN. Update on ACR TI-RADS: successes, challenges, and future directions, from the AJR Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol. 2021 Mar;216(3):570-8.全文  摘要

44. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017 May;14(5):587-95.全文  摘要

45. Rossi ED, Pantanowitz L, Faquin WC. The role of molecular testing for the indeterminate thyroid FNA. Genes (Basel). 2019 Sep 23;10(10):736.全文  摘要

46. Nishino M, Nikiforova M. Update on molecular testing for cytologically indeterminate thyroid nodules. Arch Pathol Lab Med. 2018 Apr;142(4):446-57.全文  摘要

47. Zhang L, Castellana M, Virili C, et al. Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. Eur J Endocrinol. 2019 Mar;180(3):177-87.全文  摘要

48. Novoa E, Gürtler N, Arnoux A, et al. Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck. 2012 Oct;34(10):1497-503. 摘要

49. Viola D, Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am. 2019 Mar;48(1):285-301. 摘要

50. Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63.全文  摘要

51. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020 Mar;271(3):e21-93. 摘要

52. Garau LM, Rubello D, Muccioli S, et al. The sentinel lymph node biopsy technique in papillary thyroid carcinoma: the issue of false-negative findings. Eur J Surg Oncol. 2020 Jun;46(6):967-75. 摘要

53. Garau LM, Rubello D, Morganti R, et al. Sentinel lymph node biopsy in small papillary thyroid cancer: a meta-analysis. Clin Nucl Med. 2019 Feb;44(2):107-18. 摘要

54. Albers MB, Nordenström E, Wohlfahrt J, et al. Sentinel lymph node biopsy in thyroid cancer. World J Surg. 2020 Jan;44(1):142-7. 摘要

55. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.全文  摘要

56. Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014 Jun;43(2):401-21. 摘要

57. Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019 Mar 15;104(9):4087-100.全文  摘要

58. US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017 May 9;317(18):1882-7.全文  摘要

59. Perros P, Boelaert K, Colley S, et al; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122.全文  摘要

60. Gulec SA, Ahuja S, Avram AM, et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid. 2021 Jul;31(7):1009-19.全文  摘要

61. European Society for Medical Oncology. Clinical practice guidelines - thyroid cancer. Apr 2022 [internet publication].全文

62. Saravana-Bawan B, Bajwa A, Paterson J, et al. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery. 2020 Jan;167(1):46-55. 摘要

63. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2018 Mar;44(3):307-15.全文  摘要

64. Dralle H, Machens A, Basa J, et al. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers. 2015 Dec 10;1:15077. 摘要

65. Biondi B, Cooper DS. Thyroid hormone suppression therapy. Endocrinol Metab Clin North Am. 2019 Mar;48(1):227-37. 摘要

66. Brancatella A, Marcocci C. TSH suppressive therapy and bone. Endocr Connect. 2020 Jul;9(7):R158-72.全文  摘要

67. Chen L, Wu YH, Lee CH, et al. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg. 2018 Sep;42(9):2846-57. 摘要

68. Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046.全文  摘要

69. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022 Mar 10;386(10):923-32.全文  摘要

70. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019 Apr;29(4):461-70.全文  摘要

71. Valerio L, Maino F, Castagna MG, et al. Radioiodine therapy in the different stages of differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2022 Sep 10;101703. 摘要

72. Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 2018 Aug;6(8):618-26. 摘要

73. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New Engl J Med. 2012 May 3;366(18):1674-85.全文  摘要

74. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51.全文  摘要

75. Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017 Nov 20;8:312.全文  摘要

76. Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: an American Head and Neck Society consensus statement. Head Neck. 2016 Dec;38(12):1862-9.全文  摘要

77. Verburg FA, Hänscheid H, Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):279-90. 摘要

78. Shonka DC Jr, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Jun;44(6):1277-300. 摘要

79. Li J, Zhang Y, Sun F, et al. Towards an era of precise diagnosis and treatment: role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer. Front Endocrinol (Lausanne). 2022 Sep 8;13:980582.全文  摘要

80. Brose MS, Nutting CM, Jarzab B, et al; DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26;384(9940):319-28.全文  摘要

81. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30.全文  摘要

82. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Aug;22(8):1126-38. 摘要

83. Bradford D, Larkins E, Mushti SL, et al. FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res. 2021 Apr 15;27(8):2130-5.全文  摘要

84. Rao SN, Smallridge RC. Anaplastic thyroid cancer: an update. Best Pract Res Clin Endocrinol Metab. 2022 May 27;101678. 摘要

85. Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022 Jun;51(2):391-401. 摘要

86. Hadoux J, Pacini F, Tuttle RM, et al. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71. 摘要

87. Ringel MD. New horizons: emerging therapies and targets in thyroid cancer. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e382-8.全文  摘要

88. Laetitia G, Sven S, Fabrice J. Combinatorial therapies in thyroid cancer: an overview of preclinical and clinical progresses. Cells. 2020 Mar 30;9(4):830.全文  摘要

89. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.全文  摘要

90. American Cancer Society. Thyroid cancer survival rates, by type and stage. 2022 [internet publication].全文

91. Kure S, Ohashi R. Thyroid Hürthle Cell Carcinoma: Clinical, Pathological, and Molecular Features. Cancers (Basel). 2020 Dec 23;13(1):.全文  摘要

92. Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020 Sep 1;6(9):1397-404.全文  摘要

93. Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018 Jun 21;378(25):2411-9. 摘要

94. Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018 Jun 20;36(18):1831-9.全文  摘要

95. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1;117(19):4439-46.全文  摘要

96. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011 Dec;150(6):1250-7. 摘要

97. Qi L, Zhang W, Ren X, et al. Incidence and predictors of synchronous bone metastasis in newly diagnosed differentiated thyroid cancer: a real-world population-based study. Front Surg. 2022;9:778303.全文  摘要

98. Royal College of Physicians (UK). Evidence-based indications for the use of PET-CT in the UK 2016. May 2016 [internet publication].全文

99. Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr;21(4):335-46.全文  摘要